Eptifibatide

At a glance

Overview

Eptifibatide was developed using insights from barbourin, a snake-venom peptide with selective platelet-integrin binding, but the medicine is a manufactured synthetic peptide. It inhibits platelet aggregation at a final common step rather than acting as a thrombin inhibitor. US labeling includes acute coronary syndrome without persistent ST elevation and percutaneous coronary intervention. Its practical use depends on contemporary antiplatelet treatment, procedural circumstances, and bleeding risk. Historical trials were conducted before some current approaches became common, so benefit estimates need comparator and treatment-era context. Kidney function is particularly relevant because it affects exposure and eligibility for treatment.

Supporting sources [1] [2] [3]

How it works

Eptifibatide reversibly blocks platelet glycoprotein IIb/IIIa, also called integrin alpha-IIb beta-3. This prevents fibrinogen and other adhesive ligands from bridging activated platelets, reducing aggregation. It acts downstream of many activation signals, explaining potent inhibition but also bleeding potential. The effect is different from reducing coagulation-factor activity or dissolving fibrin, and accompanying anticoagulants add a separate hemostatic effect.

Supporting sources [1] [2] [3]

Approved coronary settings

Eptifibatide is labeled to reduce specified composite ischemic outcomes in acute coronary syndromes and PCI, including coronary stenting. Selection is procedural and patient-specific, rather than a general preventive injection. The label includes contraindications involving active or recent serious bleeding, certain strokes, severe hypertension, and dialysis dependence.

Supporting sources [1]

The PURSUIT trial

PURSUIT enrolled more than 10,000 patients with acute coronary syndromes without persistent ST elevation. Eptifibatide modestly reduced the composite of death or nonfatal myocardial infarction at 30 days compared with placebo, with more bleeding. The result supports a clinical role but also shows why the ischemic benefit must be weighed against harm.

Supporting sources [2]

Platelet count and renal function matter

Serious bleeding may occur at procedure sites or elsewhere. Acute, sometimes profound thrombocytopenia is another important warning. Reduced kidney function increases exposure, and other antiplatelets or anticoagulants can compound bleeding risk. A sudden platelet fall should not be dismissed as an expected harmless consequence of platelet inhibition.

Supporting sources [1]

Why a snake-venom connection is relevant

The original barbourin research helped identify a structural motif with selectivity for the platelet receptor. That discovery informed rational drug design, not administration of crude venom. The finished medicine has a defined chemical structure and controlled clinical program; natural origin of an inspiration does not determine a drug’s safety.

Supporting sources [3]

Does eptifibatide dissolve an existing clot?

It inhibits platelet aggregation rather than directly breaking down fibrin. That distinction matters because antiplatelet and thrombolytic medicines have different roles, contraindications and risks. Eptifibatide’s evidence concerns selected acute coronary and procedural settings, where its potential reduction in ischemic events must be weighed against serious bleeding.

Supporting sources [1] [2]